UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549


FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934.







Date of Report: May       09, 2007

(Date of earliest event reported)




Corcept Therapeutics Incorporated

(Exact name of registrant as specified in its charter)





CA

(State or other jurisdiction 
of incorporation)


000-50679

(Commission File Number)


77-0487658

(IRS Employer 
Identification Number)






149 Commonwealth Drive

(Address of principal executive offices)

 

94025

(Zip Code)




650-327-3270
(Registrant's telephone number, including area code)




Not Applicable
(Former Name or Former Address, if changed since last report)








Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


 
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

  

 
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

  





Item 2.02. Results of Operations and Financial Condition



On May 9, 2007 Corcept Therapeutics issued a press release announcing its financial results for the quarter ended March 31, 2007.  The press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits


(a) Financial statements:

             None

(b) Pro forma financial information:

             None

(c) Shell company transactions:

             None

(d) Exhibits



Press Release dated May 9, 2007

             99.1       Press Release of Corcept Therapeutics Incorporated dated May       09, 2007



SIGNATURE

      Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be
              signed on its behalf by the undersigned hereunto duly authorized.








Dated: May       09, 2007



CORCEPT THERAPEUTICS INCORPORATED

By:  /s/ Anne LeDoux                      

     Anne LeDoux

     Vice President & Controller







Exhibit Index



Exhibit No.
Description


99.1
Press Release of Corcept Therapeutics Incorporated dated May       09, 2007